The inhibition of CTLA-4 enhances T cell responses to tumor-associated neoantigens, depletes local intra-tumoral Treg cells, and shifts the balance of the tumor microenvironment away from immunosuppression [17,18,19]. Here, CTLA4 is linked to neoplasm.